Eisai to Divest Rights for Pariet in China to Peak Pharma TOKYO, Apr 1, 2025 - (JCN Newswire) - Eisai Co., ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission (EC) has decided to refer the marketing authorisation approval decision of lecanemab in the ...
Leqembi — sold through a partnership between Eisai Co. and Cambridge-based Biogen — is one of the first medications approved ...
There are glimmers of hope, however, with Eisai reporting last month that it is on track to meet that fiscal 2024 sales ...
With two years of experience selling Alzheimer’s disease antibody Leqembi so far under Eisai’s belt, the Japanese drugmaker ...
BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. | BB-1701 has survived Eisai’s ...
Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...
Ad hoc announcement pursuant to Art. 53 LR Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients ...
EQS-News: Newron Pharmaceuticals S.p.A. / Key word (s): Annual Report Newron presents 2024 financial results and provides 2025 outlook 01.04.2025 / 07:00 CET/CEST The issuer is solely responsible ...
BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for Leqembi. According to Eisai's simulation, Leqembi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback